Scarica l'app Stockscreener
2.80
2.94%
0.08
Dopo l'orario di chiusura:
2.81
0.01
+0.36%
Precedente Chiudi:
$2.72
Aprire:
$2.88
Volume 24 ore:
809.20K
Relative Volume:
3.04
Capitalizzazione di mercato:
$106.54M
Reddito:
-
Utile/perdita netta:
$-27.66M
Rapporto P/E:
-2.9474
EPS:
-0.95
Flusso di cassa netto:
$-24.36M
1 W Prestazione:
-38.46%
1M Prestazione:
-38.46%
6M Prestazione:
-19.08%
1 anno Prestazione:
+9.80%
Intervallo 1D:
$2.75
$2.90
Intervallo di 1 settimana:
$2.655
$4.9883
Portata 52W:
$1.9875
$8.535
Genelux Corp Stock (GNLX) Company Profile
Nome
Genelux Corp
Settore
Industria
Telefono
805-267-9889
Indirizzo
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Confronta GNLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.80 | 103.50M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Lake Street | Buy |
| 2024-10-29 | Iniziato | Guggenheim | Buy |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-11-27 | Iniziato | H.C. Wainwright | Buy |
| 2023-09-12 | Iniziato | Maxim Group | Buy |
| 2023-02-15 | Iniziato | The Benchmark Company | Speculative Buy |
Mostra tutto
Genelux Corp Borsa (GNLX) Ultime notizie
Can Genelux Corporation stock sustain revenue growth2025 Earnings Surprises & AI Powered Trade Plan Recommendations - ulpravda.ru
Genelux Announces Underwritten Public Offering to Raise Capital - TipRanks
Genelux Corp Announces $20 Million Public Offering - TradingView — Track All Markets
Genelux Corporation announces pricing of $20.0 million underwritten public offering of common stock - MarketScreener
Genelux prices public offering of 6.67 million shares at $3 each - Investing.com Australia
Genelux prices public offering of 6.67 million shares at $3 each By Investing.com - Investing.com South Africa
Genelux Corporation Announces Pricing of $20 Million Public Offering of Common Stock - Quiver Quantitative
Genelux stock falls after announcing proposed public offering By Investing.com - Investing.com Canada
Genelux stock falls after announcing proposed public offering - Investing.com
Genelux announces proposed public offering of common stock - Investing.com
Genelux Corporation Announces Proposed Public Offering of Common Stock - MarketScreener
Cancer-focused biotech Genelux plans new public stock sale to investors - Stock Titan
Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors - simplywall.st
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - Nasdaq
Genelux data update indicates disease early control, says H.C. Wainwright - TipRanks
Genelux reports encouraging interim data for Olvi-Vec trials - MSN
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data By Investing.com - Investing.com South Africa
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data - Investing.com Canada
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer - TipRanks
Genelux reports interim data of systemic administration of Olvi-Vec - TipRanks
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials - TipRanks
Experimental treatment shrank lung tumors up to 85% in early trial - Stock Titan
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - Sahm
Genelux (NASDAQ:GNLX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Genelux appoints Jason Litten as chief medical officer By Investing.com - Investing.com Nigeria
Genelux Appoints Veteran Oncologist Jason Litten as CMO - TipRanks
Genelux appoints Jason Litten as CMO - TipRanks
Genelux Corporation Announces Change of Chief Medical Officer - MarketScreener
Genelux appoints Jason Litten as chief medical officer - Investing.com India
Genelux Corporation Appoints Dr. Jason Litten as Chief Medical Officer to Advance Olvi-Vec Development - Quiver Quantitative
GENELUX CORP : BENCHMARK CUTS TARGET PRICE TO $23 FROM $25 - 富途牛牛
How interest rate cuts could boost Genelux Corporation stockAnalyst Upgrades & AI Alerts You Can Actually Trust - Bollywood Helpline
Flputnam Investment Management Co. Raises Holdings in Genelux Corporation $GNLX - MarketBeat
Genelux (NASDAQ:GNLX) Cut to Sell at Wall Street Zen - Defense World
Cappello, Genelux CTO, sells $14k in GNLX stock By Investing.com - Investing.com Nigeria
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 4,509 Shares - MarketBeat
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 12,673 Shares of Stock - MarketBeat
Genelux SVP, Yu Yong, sells shares worth $16k By Investing.com - Investing.com Australia
Genelux president sells $66k in GNLX stock By Investing.com - Investing.com Australia
Genelux SVP, Yu Yong, sells shares worth $16k - Investing.com
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView — Track All Markets
VP Yu Surrenders 4,192 Of Genelux Corp [GNLX] - TradingView — Track All Markets
Genelux reports Q3 EPS (21c), consensus (21c) - MSN
Lake Street Sticks to Their Buy Rating for Genelux Corp. (GNLX) - The Globe and Mail
Genelux price target raised to $20 from $10 at Maxim - MSN
Genelux (NASDAQ:GNLX) Director Sells $50,000.00 in Stock - MarketBeat
Genelux (GNLX) Stock Analysis Report | Financials & Insights - Benzinga
GENELUX Corp Director Thomas John Sells 10,000 Shares - TradingView
Dir Thomas Sells 10,000 ($50K) Of Genelux Corp [GNLX] - TradingView
Wall Street analysts’ outlook for Genelux Corp (GNLX) - Setenews
Global Retirement Partners LLC Acquires Shares of 228,676 Genelux Corporation $GNLX - MarketBeat
Genelux Corp Azioni (GNLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Genelux Corp Azioni (GNLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Yu Yong | SVP, Clinical Development |
Nov 17 '25 |
Sale |
5.37 |
973 |
5,224 |
145,844 |
| Zindrick Thomas | President and CEO |
Aug 21 '25 |
Sale |
3.33 |
12,673 |
42,159 |
542,940 |
| Zindrick Thomas | President and CEO |
Nov 17 '25 |
Sale |
5.37 |
4,509 |
24,211 |
538,431 |
| Cappello Joseph | Chief Technical Officer |
Aug 21 '25 |
Sale |
3.34 |
2,733 |
9,137 |
157,033 |
| Cappello Joseph | Chief Technical Officer |
Nov 17 '25 |
Sale |
5.37 |
973 |
5,224 |
156,060 |
| Smalling Ralph | Head of Regulatory |
Aug 21 '25 |
Sale |
3.36 |
1,244 |
4,177 |
69,746 |
| Smalling Ralph | Head of Regulatory |
Sep 03 '25 |
Sale |
3.36 |
580 |
1,948 |
69,166 |
| Smalling Ralph | Head of Regulatory |
Nov 17 '25 |
Sale |
5.37 |
343 |
1,842 |
68,823 |
| Smalling Ralph | Head of Regulatory |
Dec 05 '25 |
Sale |
4.69 |
165 |
774 |
68,658 |
| Thomas John | Director |
Dec 01 '25 |
Sale |
5.00 |
10,000 |
50,008 |
492,784 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):